Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. - Wikidata - wikimedia - TriplyDB

Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.

Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.

http://www.wikidata.org/entity/Q34589922

about

Antipsychotic dosing: found in translation An intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes?Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment Classics in Chemical Neuroscience: Aripiprazole.Evaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release.Calculating occupancy when one does not have baseline: a comparison of different options Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship Adverse Effects and Toxicity of the Atypical Antipsychotics: What is Important for the Pediatric Emergency Medicine Practitioner Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review Antipsychotic occupancy of dopamine receptors in schizophrenia.The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia.Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.Pharmacokinetics and metabolism update for some recent antipsychotics.Serotonin 2A receptor antagonists for treatment of schizophrenia.Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.Aripiprazole: a review of its use in the management of schizophrenia in adults.Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.In vitro and initial in vivo evaluation of (68)Ga-labeled transferrin receptor (TfR) binding peptides as potential carriers for enhanced drug transport into TfR expressing cells.Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability.Effects of antipsychotic treatment on cognition in healthy subjects.Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain.Intramuscular aripiprazole in the acute management of psychomotor agitation.Aripiprazole in the treatment of challenging behaviour in adults with autism spectrum disorder.The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: a high-resolution PET study with [(18)F]fallypride.Quantitative projection of human brain penetration of the H3 antagonist PF-03654746 by integrating rat-derived brain partitioning and PET receptor occupancy.Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.

P2860

Q26863343-D6378F20-8C00-49D7-9D32-3D2A1AD065D7 Q27491346-881EB505-4183-428B-B95E-9E4D646A69D0 Q28084069-F5906AED-DE15-4C82-8F2D-B8B2E0EB2315 Q28484113-33E772B5-1488-4D83-BDDB-B692095EAF40 Q28972478-7605A441-5239-4314-9B98-1AB6D4107D13 Q33866125-99F9521B-C9AD-4075-8077-668C37CBFD45 Q35103315-20634ED6-3762-4C32-A42B-4DDE06D1C456 Q35208019-7B1E0A00-216B-4E5F-B008-B3F2009DF433 Q35866868-BD44C80A-539E-4A68-9DF1-D1B19FF7B522 Q36653419-A0667CC2-D7B9-401E-9407-EAF2E00AA174 Q36920020-CC0DD883-8493-4EBA-BC3A-C100ABCC4FA9 Q37175786-FDD01E7F-3EFF-4DFE-A358-7D6EAD19D00E Q37299210-FF64EC2D-6434-4A89-8F6C-8AEF96F02BC1 Q37818511-D2721BC0-A5CE-4986-8974-880F9030FABD Q37820985-146E244C-9442-4202-BB4F-410BED0CD95E Q37862242-FDF26C1B-46FB-4F85-8D28-6E2BACA81866 Q37863118-740E4DA5-E7AF-4642-B555-E9E80EE52A86 Q37899193-85282FF2-D997-4680-9FFE-F8622B2EC4E2 Q37970762-44F0B887-3BC7-4D9E-9E81-FD16BD945A47 Q37980517-26CEC750-67F8-4D18-9315-EFF25B4FC1E3 Q38204833-6B6D0705-1921-4633-904E-2646B718D279 Q39703349-31D46E34-4AC9-4008-B976-8F83734F29A2 Q39959170-7124C495-C99D-4BA5-B41B-A5EEF4259072 Q43584036-DF8AC645-B5B2-45EA-9641-6AD093D240BA Q44009699-0CDA7016-CDA4-48CD-AB6A-C0D7E3F3511C Q44510576-092A7FC7-EE4D-4536-A08B-644238FC1D47 Q45743617-CED974D6-C1B4-488C-AB00-BFB042759BEC Q46128379-44B72291-0786-45A9-A9B6-406E2D005D72 Q46599084-6324A05D-A94C-4083-AF48-24103857E6DA Q46703897-095839A3-CD40-4A9D-AC03-8E5F150B7D2C Q47850608-F4DB3179-7FC8-4130-A920-891FA4DC9E24 Q48010897-295A4753-E185-495E-A6E8-24FBFC1F0A88 Q48651489-C1B6899E-EDD5-4D63-8B5B-B1919B4D14A2 Q50739337-C4299180-7354-40E3-B34D-FB0431559CEA

P2860

Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.

http://www.wikidata.org/entity/Q34589922

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Brain and plasma pharmacokinet ...... an [18F]fallypride PET study.

@ast

Brain and plasma pharmacokinet ...... an [18F]fallypride PET study.

@en

Brain and plasma pharmacokinet ...... an [18F]fallypride PET study.

@nl

type

label

Brain and plasma pharmacokinet ...... an [18F]fallypride PET study.

@ast

Brain and plasma pharmacokinet ...... an [18F]fallypride PET study.

@en

Brain and plasma pharmacokinet ...... an [18F]fallypride PET study.

@nl

prefLabel

Brain and plasma pharmacokinet ...... an [18F]fallypride PET study.

@ast

Brain and plasma pharmacokinet ...... an [18F]fallypride PET study.

@en

Brain and plasma pharmacokinet ...... an [18F]fallypride PET study.

@nl

P1433

Q34589922-9114C208-D09F-4E42-9492-DFD79CFA2B13

P1476

Q34589922-2C624269-93AB-440E-ACB3-FE5F83998753

P2093

Q34589922-2467ED06-6546-4D52-B4FE-D8A4B93CA683

Q34589922-4E7F4D21-E3FF-465C-83B6-7DC037243417

Q34589922-5722030D-6A65-4ED6-9EEC-3338B183E437

Q34589922-5B3E69FE-B6CA-4E1B-B8EE-931D41C22903

Q34589922-8C7FBB43-60A5-43A8-9458-E181EF24F371

Q34589922-8CE90374-0B51-41A4-BC84-26E593B90E88

Q34589922-955ECECB-E811-4C65-8A4A-DDF6BD0C538D

Q34589922-C4E4E6DF-79FA-498C-B24E-6A01A21935E2

Q34589922-D89F61E2-6863-435B-9910-54BBEFFB8992

Q34589922-DD6BB672-5168-4C41-A522-297D9450B6FE

P304

Q34589922-D2D0AD5A-5080-4EC6-96AD-17943445AB40

P31

Q34589922-9F172D19-D630-4F0C-B296-8EFBC02E33D8

P356

Q34589922-4BFD1CD1-A380-437B-A49C-BE4E997C71A8

P407

Q34589922-71343F1B-8E64-42FA-ADD6-2A44EC47663A

P433

Q34589922-58337EE6-3322-4CB4-9873-B26A0F5BA057

P478

Q34589922-24952FB1-6A4A-477B-BBF2-77F91A158ED8

P577

Q34589922-B51865AD-9781-4C4C-BEFF-C85021967A64

P5875

Q34589922-BE34F0A9-6E04-410B-AD3F-88BA127D4B47

P698

Q34589922-35AED0C7-3C70-40B0-95B3-4A30A16272EC

P921

Q34589922-EDE8CD26-DB19-4858-A6C2-E497771607BC

P356

APPI.AJP.2008.07101574

P1433

American Journal of Psychiatry

P1476

Brain and plasma pharmacokinet ...... an [18F]fallypride PET study.

@en

P2093

Anno Bröcheler

http://www.w3.org/2001/XMLSchema#string

Christian Boy

http://www.w3.org/2001/XMLSchema#string

Christine Fellows

http://www.w3.org/2001/XMLSchema#string

Christoph Hiemke

http://www.w3.org/2001/XMLSchema#string

Frank Rösch

http://www.w3.org/2001/XMLSchema#string

Gerhard Gründer

http://www.w3.org/2001/XMLSchema#string

Hildegard Janouschek

http://www.w3.org/2001/XMLSchema#string

Ingo Vernaleken

http://www.w3.org/2001/XMLSchema#string

Katja M Spreckelmeyer

http://www.w3.org/2001/XMLSchema#string

Katrin M Kirschbaum

http://www.w3.org/2001/XMLSchema#string

P304

988-995

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1176/APPI.AJP.2008.07101574

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

165

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5470587

http://www.w3.org/2001/XMLSchema#string

P698

18381901

http://www.w3.org/2001/XMLSchema#string

P921